

PRODUCT INFORMATION

|                              |  |
|------------------------------|--|
| Clone ID                     | 17E6   |
| Target                       | GFAP   |
| Synonyms                     | ALXDRD   |
| Host Species                 | Rabbit   |
| Description                  | Biotinylated Anti-GFAP(68-377) antibody(17E6), Rabbit mAb  |
| Delivery                     | 2-3 weeks  |
| Uniprot ID                   | P14136   |
| IgG type                     | Rabbit IgG   |
| Clonality                    | Monoclonal   |
| Reactivity                   | Human  |
| Applications                 | ELISA  |
| Recommended Dilutions        | ELISA 1:5000-10000   |
| Purification                 | Purified from cell culture supernatant by affinity chromatography  |
| Formulation & Reconstitution | Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.   |
| Storage & Shipping           | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature.  |
| Background                   | This gene encodes one of the major intermediate filament proteins of mature astrocytes. It is used as a marker to distinguish astrocytes from other glial cells during development. Mutations in this gene cause Alexander disease, a rare disorder of astrocytes in the central nervous system. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Oct 2008] |
| Usage                        | Research use only  |
| Conjugate                    | Biotinylated   |
| DIMA Disclaimer              | All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement.   |

